Impact of Valprazolamide on the Exploratory Behavior in Mice

Malygin A. S.
Resident Physician, Chair for Pharmacology and Clinical Pharmacology¹

Lomonosova I. A.
Cand. Biol. Sci. Assistant, Chair for Management and Economic of Pharmacy¹

Bogomolova O. A.
Assistant, Chair for Management and Economic of Pharmacy¹

Demidova M. A.
Doctor of Medicine, Full Professor, Head, Chair for Management and Economic of Pharmacy¹

1 - Tver State Medical University, Tver, Russia

Lomonosova Irina; e-mail: Itabira@yandex.ru

None declared.

The study had no sponsorship.

The effect of valprazolamide, a new antiepileptic agent from the group of amide derivatives of valproic acid, on the exploratory behavior of mice in «open field» test and a «dark/light transition» test was studied. As a result of the experiment, it was revealed that the new antiepileptic drug valprazolamide, when used in doses of 75 mg/kg and 150 mg/kg, hadn’t a significant effect on the orienting-exploratory behavior of mice. With a single intraperitoneal injection at a dose of 300 mg/kg, individual manifestations of rodent research activity increased (horizontal locomotor activity when tested in the open field), and at a dose of 450 mg / kg, it had a depressing effect on the orientation reflexes in rodents.

valproates, antiepileptics, exploratory behavior

10.29234/2308-9113-2018-6-4-109-119

1. Bogomolova O.A., Demidova M.A. Vliyaniye novykh proizvodnykh 3-oksipiridina na oriyentirovochno-issledovatel'skoye povedeniye krys [The effect of new 3-hydroxypyridine derivatives on the orienting-exploratory behavior in rats]. Verkhnevolzhskiy meditsinskiy zhurnal [Upper Volga Medical Journal] 2015; 14 (4): S. 33-37. (In Russ.)

2. Voronina T.A., Garibova T.L., Krayneva V.A. Povedencheskiye eksperimental'nyye modeli depressii [Behavioral experimental models of depression]. Farmakokinetika i farmakodinamika [Pharmacokinetics and Pharmacodynamics] 2017; 3: 14-19. (In Russ.)

3. Dzhagatspanyan I.A., Paronikyan R.G., Nazaryan I.M. Eksperimental'naya kharakteristika neyrotropnogo spektra nekotorykh antiepilepticheskikh preparatov [Experimental characterization of the neurotropic spectrum of some anti-epileptic drugs]. Eksperimental'naya i klinicheskaya farmakologiya [Experimental and Clinical Pharmacology] 2003; 66 (6): 20-23. (In Russ.)

4. Mironov A.N. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv [Guidelines for conducting preclinical studies of drugs]. Moscow: Grif i K., 2012. 944 s. (In Russ.)

5. Pat. 2651572 Rossiyskaya Federatsiya, MPK A 61 K 31/433 N- (5-Etil-1,3,4-tiadiazol-2-il) -2-propilpentanamid, obladayushchiy protivoepilepticheskoy i obezbolivayushchey aktivnostyami / S.Ya. Skachilova, A.S.Malygin, N.S.Popov [i dr.]; zayavitel' i patentoobladatel' OAO VNTS BAV. – № 267288; zayavl. 13.03.2018; opubl. 20.11.2018, Byul. № 32. [Patent 2651572, Russian Federation, IPC A 61 K 31/433 N- (5-Ethyl-1,3,4-thiadiazol-2-yl) -2-propylpentanamide, which has antiepileptic and analgesic activities. S.Y. Skachilova, A.S. Malygin, N.S. Popov [et al.]; applicant and patent holder of JSC VNTS BAV. – № 267288; declare 03/13/2018; publ. 11/20/2018 Bull. No. 32.]

6. Prikaz MZ RF ot 01.04.2016 № 199n «Pravila optimal'noy laboratornoy praktiki» [Order of the Ministry of Health of the Russian Federation of 01.04.2016 No. 199n «Rules of Good Laboratory Practice»] (In Russ.)

7. Freydkova N.V., Pylayeva O.V., Mukhin K.Yu. Val'parin KHR v lechenii epilepsii (obzor literatury i opisaniya klinicheskikh sluchayev) [Valparin KHR in the treatment of epilepsy (review of the literature and description of clinical cases)]. Russkiy zhurnal detskoy nevrologii [Russian Journal of Pediatric Neurology] 2015; 10 (3): 37-42. (In Russ.)

8. Shnayder N.A. Dmitrenko D.V. Khronicheskaya intoksikatsiya val'proyevoy kislotoy v epileptologii: diagnostika i lecheniye [Chronic intoxication with valproic acid in epileptology: diagnosis and treatment]. Nevrologiya, neyropsikhiatriya, psikhosomatika [Neurology, neuropsychiatry, psychosomatics] 2016; 8 (2): 94-99. (In Russ.)

9. Perukka Ye. Farmakologicheskiye i terapevticheskiye svoystva val'proata: rezyume posle 35 let klinicheskogo opyta. CNS Drugs 2012; 16 (10): 695-714.